Evidence map›Paper›PMID 38659142›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2024

Facilitators and barriers to adolescent participation in a TB clinical trial.

J M Mangan, K N C Hedges, M M Salerno, K Tatum, B Bouwkamp, M W Frick, L McKenna, G Muzanyi, M Engle, J Coetzee and 10 more

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 13 institutions in 4 countries.

J M ManganDivision of Tuberculosis Elimination, Centers for Disease Control, Atlanta, GA.
K N C HedgesDivision of Tuberculosis Elimination, Centers for Disease Control, Atlanta, GA.
M M SalernoBureau of Tuberculosis Control, New York City Department of Health and Mental Hygiene, New York, NY.
K TatumDivision of Tuberculosis Elimination, Centers for Disease Control, Atlanta, GA.
B BouwkampDivision of Tuberculosis Elimination, Centers for Disease Control, Atlanta, GA, Oak Ridge Institute for Science and Education.
M W FrickTreatment Action Group, New York, NY, USA.
L McKennaTreatment Action Group, New York, NY, USA.
G MuzanyiUganda-Case Western Reserve University Research Collaboration, Kampala, Uganda.
M EngleUTHSCSA & San Antonio Veterans Administration Medical Center, TX, USA.
J CoetzeeFamily Centre for Research with Ubuntu, University of Stellenbosch, Capetown, South Africa.
J YvetotLes Centres GHESKIO, Port Au Prince, Haïti.
M ElskampBureau of Tuberculosis Control, New York City Department of Health and Mental Hygiene, New York, NY.
D LamunuUganda National Council for Science and Technology, Kampala, Uganda.
M E Theunissen TizoraFamily Centre for Research with Ubuntu, University of Stellenbosch, Capetown, South Africa.
D NamutambaInternational Community of Women Living with HIV Eastern Africa, Bujumbura, Burundi.
R E ChaissonJohns Hopkins University, Baltimore, MD.
S SwindellsUniversity of Nebraska Medical Center, Omaha, NE.
P NahidUCSF Center for Tuberculosis, University of California, San Francisco, CA.
S E DormanMedical University of South Carolina, Charleston, SC, USA.
E KurbatovaDivision of Tuberculosis Elimination, Centers for Disease Control, Atlanta, GA.
Centers for Disease Control and Prevention · USNew York City Department of Health and Mental Hygiene · USStellenbosch University · ZATreatment Action Group · USGheskio Centers · HTJohns Hopkins University · USMedical University of South Carolina · USMUJHU Research Collaboration · UGOak Ridge Institute for Science and EducationThe University of Texas Health Science Center at San Antonio · USUganda National Council for Higher Education · UGUniversity of California, San Francisco · USUniversity of Nebraska Medical Center · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
GHESKIO HIV Clinical Trial UnitUM1AI069421 · NIAID · GHESKIO CENTER · PI JEAN WILLIAM PAPE · 2012 to 2026
$23.6M
Intramural CDC HHS CC999999NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069421NIAID NIH HHS UM1 AI106701
6 · The paper itself

Abstract

<sec id="st1"><title>BACKGROUND</title>The inclusion of adolescents in TB drug trials is essential for the development of safe, child-friendly regimens for the prevention and treatment of TB. TB Trials Consortium Study 31/AIDS Clinical Trials Group A5349 (S31/A5349) enrolled adolescents as young as 12 years old. We assessed investigator and coordinator described facilitators and barriers to adolescent recruitment, enrollment, and retention.</sec><sec id="st2"><title>METHODS</title>Interviews were conducted with six investigators from sites that enrolled adolescent participants and six investigators from non-enrolling sites. Additionally, two focus groups were conducted with study coordinators from enrolling sites and two focus groups with non-enrolling sites. Discussions were transcribed, analyzed, summarized, and summaries were reviewed by Community Research Advisors Group members and research group representatives for content validity.</sec><sec id="st3"><title>RESULTS</title>Investigators and coordinators attributed the successful enrollment of adolescents to the establishment and cultivation of external partnerships, flexibility to accommodate adolescents' schedules, staff engagement, recruitment from multiple locations, dedicated recruitment staff working onsite to access potential participants, creation of youth-friendly environments, and effective communications. Non-enrolling sites were mainly hindered by regulations. Suggestions for improvement in future trials focused on study planning and site preparations.</sec><sec id="st4"><title>CONCLUSION</title>Proactive partnerships and collaboration with institutions serving adolescents helped identify and reduce barriers to their inclusion in this trial.</sec>.

Indexed as

Focus GroupsPatient SelectionTuberculosisAdolescentAntitubercular AgentsChildClinical Trials as TopicFemaleHumansMaleResearch PersonnelAntitubercular Agents

Identifiers

PMID38659142
PMCPMC11500608
OpenAlexW4395456848

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.